152170-30-4

Usage

Uses

Used in Pharmaceutical Industry:
2-chloro-Thiazolo[4,5-b]pyridine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and properties make it a valuable building block in the development of new drugs, particularly those targeting specific biological pathways or receptors.
Used in Chemical Research:
2-chloro-Thiazolo[4,5-b]pyridine is used as a research compound in academic and industrial laboratories. It serves as a model compound for studying the properties and reactivity of Thiazolopyridines, as well as for exploring new synthetic routes and methodologies in organic chemistry.
Used in Material Science:
2-chloro-Thiazolo[4,5-b]pyridine is used as a component in the development of novel materials with specific properties, such as electronic, optical, or catalytic functions. Its incorporation into polymers or other materials can lead to new applications in areas like sensors, energy storage, or catalysis.
Used in Environmental Applications:
2-chloro-Thiazolo[4,5-b]pyridine may be used in the development of environmental remediation technologies, such as in the design of new adsorbents or catalysts for the removal of pollutants from air, water, or soil. Its chemical properties could potentially be harnessed to improve the efficiency of these processes.

InChI:InChI=1/C6H3ClN2S/c7-6-9-5-4(10-6)2-1-3-8-5/h1-3H

Upstream product

• 152170-29-1 thiazolo<4,5-b>pyridine-2(3H)-one 
• 99158-61-9 thiazolo[4,5-b]pyridine-2(3H)-thione 
• 152170-28-0 2-amino-3-dimethylcarbamoylthiopyridine 
• 15128-82-2 3-hydroxy-2-nitropyridine 
• 99158-61-9 2-mercaptothiazolo[4,5-b]pyridine 
• 152170-27-9 N,N-dimethyl-1-[(2-nitropyridin-3-yl)sulfanyl]formamide 
• 152170-26-8 N,N-dimethyl-1-[(2-nitropyridin-3-yl)oxy]methanethioamide 

Downstream Products

• 1190927-35-5 2-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)phenyl]ethanol 

Relevant academic research and scientific papers

BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS

Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

BICYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to novel Bicyclic Heterocyclic Derivatives, pharmaceutical compositions comprising the Bicyclic Heterocyclic Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a cognitive disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

Synthesis and structure-activity relationships of 2-(1,4′-bipiperidin-1′-yl)thiazolopyridine as H3 receptor antagonists

A series of 2-(1,4′-bipiperidine-1′-yl)thiazolopyridines was synthesized and evaluated as a new lead of non-imidazole histamine H3 receptor antagonists. Introduction of diversity at the 6-position of the pyridine ring was designed to enhance in vitro potency and decrease hERG activity. The structure-activity relationships for these new thiazolopyridine antagonists are discussed.

NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are phannaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY

This invention relates to certain biphenyl-4-yl carbonylamino acid compounds, compositions, and methods for treating or preventing obesity and related diseases.

Deoxygenation of polyphenols by ascomycetes : kinetic behaviour of the NADPH-dependent naphthol dehydrogenase and inhibition by tricyclazole and its analogues

The mode of action of tricyclazole, a systemic fungicide that specifically inhibits the biosynthesis of fungal melanins, has been studied with the purified naphthol reductase from Pyricularia oryzae.The NADPH-dependent naphthol reductase transforms 1,3,6,8-tetrahydroxy-naphthalene (T4HN) into (+)scytalone and 1,3,8-trihydroxynaphthalene (T3HN) into (-)vermelone, and is very strongly inhibited by tricyclazole.Kinetic analysis reveals that the inhibition is noncompetitive with respect to T4HN or T3HN, and uncompetitive with respect to NADPH.An aza-analogue of tricyclazole has been synthesized and tested.Unexpectedly, it appears to be a competitive inhibitor of T4HN in spite of its similarity to tricyclazole. Keywords: melanin biosynthesis / polyphenol deoxygenation / naphthol dehydrogenase